Zinger Key Points
- io-Path Holdings' stock skyrocketed 203.3% after announcing promising preclinical results for BP1001-A as a potential treatment for obesity
- BP1001-A demonstrated enhanced insulin sensitivity by downregulating Grb2, supporting its potential efficacy.
- Wall Street veteran Chris Capre is going live April 9 at 6 PM ET to reveal a short-term strategy that just returned 195%—in the middle of a crashing market.
Bio-Path Holdings, Inc. BPTH shares are surging Thursday following the company's announcement of encouraging preclinical results for BP1001-A, a potential treatment for obesity and Type 2 diabetes. Here’s what you need to know.
What To Know: The preclinical studies demonstrated that BP1001-A enhances insulin sensitivity by downregulating the growth factor receptor-bound protein 2. These findings suggest BP1001-A could improve insulin-induced metabolic processes and offer a new therapeutic option for obesity-related metabolic conditions.
Following these findings, the company began animal studies to validate the efficacy of BP1001-A. Pending success, the company plans on holding a first-in-human Phase 1 clinical trial in 2025 to assess safety, pharmacokinetics, and dosing.
BPTH Price Action: Bio-Path Holdings shares were up 104.8% at $1.37 at the time of writing, according to Benzinga Pro.
Read Next:
Image Via Shutterstock.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
